Adjunctive Pharmacological Therapies in the Management of Proliferative Vitreoretinopathy

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-319-78446-5_3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cannabinoid 2 receptor is a novel anti‐inflammatory target in experimental proliferative vitreoretinopathy

  2017cited by this paper
• Role of Caveolin-1 for Blocking the Epithelial-Mesenchymal Transition in Proliferative Vitreoretinopathy.

  2017cited by this paper
• EFFICACY OF INTRAVITREAL INJECTION OF BEVACIZUMAB IN VITRECTOMY FOR PATIENTS WITH PROLIFERATIVE VITREORETINOPATHY RETINAL DETACHMENT: A Meta-analysis of Prospective Studies

  2017cited by this paper
• Intraocular Dexamethasone Implant as Adjunct to Silicone Oil Tamponade for Proliferative Vitreoretinopathy

  2017cited by this paper
• Resveratrol inhibits transforming growth factor-β2-induced epithelial-to-mesenchymal transition in human retinal pigment epithelial cells by suppressing the Smad pathway

  2017cited by this paper
• Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy

  2017cited by this paper
• Slow-Release Dexamethasone in Proliferative Vitreoretinopathy: A Prospective, Randomized Controlled Clinical Trial.

  2017cited by this paper
• Clinical Guidelines for Management of Bone Health in Rett Syndrome Based on Expert Consensus and Available Evidence

  2016cited by this paper
• Epithelial-to-Mesenchymal Transition of RPE Cells In Vitro Confers Increased β1,6-N-Glycosylation and Increased Susceptibility to Galectin-3 Binding

  2016cited by this paper
• Effect of Serial Intrasilicone Oil Bevacizumab Injections in Eyes With Recurrent Proliferative Vitreoretinopathy Retinal Detachment.

  2016cited by this paper
• Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences.

  2016cited by this paper
• Role of epithelial-mesenchymal transition in proliferative vitreoretinopathy.

  2016cited by this paper
• Intravitreal Injection of Bevacizumab in Primary Vitrectomy to Decrease the Rate of Retinal Redetachment: A Randomized Pilot Study

  2016cited by this paper
• Resveratrol inhibits epithelial-mesenchymal transition of retinal pigment epithelium and development of proliferative vitreoretinopathy

  2015cited by this paper
• The Effects of Ozurdex® (Dexamethasone Intravitreal Implant) on Experimental Proliferative Vitreoretinopathy

  2015cited by this paper
• CLINICAL MANAGEMENT OF PROLIFERATIVE VITREORETINOPATHY: An Update

  2015cited by this paper
• Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy

  2015cited by this paper
• Oral colchicine for prevention of proliferative vitreoretinopathy: a randomized clinical trial

  2015cited by this paper
• 5-Fluorouracil for glaucoma surgery.

  2014cited by this paper
• IV.F. Pharmacotherapy of Proliferative Vitreoretinopathy

  2014cited by this paper
• MicroRNA-29b regulates TGF-β1-mediated epithelial-mesenchymal transition of retinal pigment epithelial cells by targeting AKT2.

  2014cited by this paper
• Comment on ‘Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy’

  2014cited by this paper
• The retinal pigment epithelium: an important player of retinal disorders and regeneration.

  2014cited by this paper
• Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery.

  2013cited by this paper
• Systematic techniques for assisting recruitment to trials (START): developing the science of recruitment

  2013cited by this paper
• Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

  2013cited by this paper
• Rhegmatogenous Retinal Detachment with a High Risk of Proliferative Vitreoretinopathy Treated with Episcleral Surgery and an Intravitreal Dexamethasone 0.7-mg Implant

  2013cited by this paper
• Ozurdex® (a slow-release dexamethasone implant) in proliferative vitreoretinopathy: study protocol for a randomised controlled trial

  2013cited by this paper
• Mechanisms of Inflammation in Proliferative Vitreoretinopathy: From Bench to Bedside

  2012cited by this paper
• Vascular Endothelial Growth Factor A Competitively Inhibits Platelet-Derived Growth Factor (PDGF)-Dependent Activation of PDGF Receptor and Subsequent Signaling Events and Cellular Responses

  2012cited by this paper
• Proliferative vitreoretinopathy: current and emerging treatments

  2012cited by this paper
• Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial

  2012cited by this paper
• Interplay between Human Cytomegalovirus and Intrinsic/Innate Host Responses: A Complex Bidirectional Relationship

  2012cited by this paper
• ANTIANGIOGENIC ISOFORMS OF VASCULAR ENDOTHELIAL GROWTH FACTOR PREDOMINATE IN SUBRETINAL FLUID OF PATIENTS WITH RHEGMATOGENOUS RETINAL DETACHMENT AND PROLIFERATIVE VITREORETINOPATHY

  2012cited by this paper
• Vitreous Vascular Endothelial Growth Factor Concentrations in Proliferative Diabetic Retinopathy versus Proliferative Vitreoretinopathy

  2011cited by this paper
• Vitreous Levels of VEGF, IL-8, and TNF-α in Retinal Detachment

  2010cited by this paper
• N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy.

  2010cited by this paper
• Effect of Oral Prednisolone on Visual Outcomes and Complications after Scleral Buckling

  2010cited by this paper
• Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy.

  2008cited by this paper
• One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy

  2008cited by this paper
• THE SAFETY OF INTRAOCULAR METHOTREXATE IN SILICONE-FILLED EYES

  2008cited by this paper
• Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial.

  2008cited by this paper
• Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy.

  2007cited by this paper
• Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy.

  2007cited by this paper
• Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma.

  2006cited by this paper
• Prevention of Proliferative Vitreoretinopathy

  2005cited by this paper
• Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy.

  2005cited by this paper
• Evaluation of a single intravitreal injection of 5-fluorouracil in vitrectomy cases

  2005cited by this paper
• [Vitrectomy with daunorubicin].

  2004cited by this paper
• RESOURCES INVOLVED IN MANAGING RETINAL DETACHMENT COMPLICATED BY PROLIFERATIVE VITREORETINOPATHY

  2004cited by this paper
• Effects of subconjunctival 5-fluorouracil injections on the corneal endothelium and ciliary epithelium

  2004cited by this paper
• Toxic effects of subconjunctival 5-fluorouracil and mitomycin C on ciliary body of rats

  2004cited by this paper
• Postoperative retinal fibrosis — a controlled clinical study of systemic steroid therapy

  2004cited by this paper
• Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy.

  2003cited by this paper
• Inverse levels of pigment epithelium-derived factor and vascular endothelial growth factor in the vitreous of eyes with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.

  2002cited by this paper
• Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery

  2002cited by this paper
• Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial.

  2001cited by this paper
• The Effect of Prinomastat (AG3340), a Synthetic Inhibitor of Matrix Metalloproteinases, on Posttraumatic Proliferative Vitreoretinopathy

  2000cited by this paper
• The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy.

  2000cited by this paper
• Biological effects of resveratrol.

  2000cited by this paper
• Concentration of Vascular Endothelial Growth Factor in the Subretinal Fluid of Retinal Detachment

  2000cited by this paper
• A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy.

  1998cited by this paper
• Effects of single, short term exposures of human retinal pigment epithelial cells to thiotepa or 5-fluorouracil: implications for the treatment of proliferative vitreoretinopathy

  1998cited by this paper
• Proliferative vitreoretinopathy: an overview.

  1998cited by this paper
• Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group.

  1998cited by this paper
• Resveratrol: a molecule whose time has come? And gone?

  1997cited by this paper
• Antiproliferative effect of retinoic acid in 1% sodium hyaluronate in an animal model of PVR.

  1997cited by this paper
• 13-cis-retinoic acid in silicone-fluorosilicone copolymer oil in a rabbit model of proliferative vitreoretinopathy.

  1997cited by this paper
• Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy.

  1997cited by this paper
• Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?

  1996cited by this paper
• Retinal Tolerance of Intravitreal Low-Molecular-Weight Heparin, Colchicine or Interferon ß Determined by Eye-Cup ERG in Albino Rabbits

  1995cited by this paper
• The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy.

  1995cited by this paper
• Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment.

  1995cited by this paper
• Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy.

  1993cited by this paper
• AN OVERVIEW OF POTENTIAL APPLICATIONS OF HEPARIN IN VITREORETINAL SURGERY

  1992cited by this paper
• Five-minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon's capsule fibroblasts.

  1992cited by this paper
• Inhibition of intraocular fibrin formation following infusion of low-molecular-weight heparin during vitrectomy.

  1991cited by this paper
• Proliferative vitreoretinopathy: does oral low-dose colchicine have an inhibitory effect? A controlled study in humans.

  1989cited by this paper
• A prospective, randomized, clinical trial of heparin therapy for postoperative intraocular fibrin.

  1988cited by this paper
• Oral colchicine for the treatment of experimental traction retinal detachment.

  1986cited by this paper
• Breakdown and reestablishment of blood-aqueous barrier with laser trabeculoplasty.

  1984cited by this paper
• Ocular toxicity of fluorouracil after vitrectomy.

  1983cited by this paper
• Fluorouracil for the treatment of massive periretinal proliferation.

  1982cited by this paper
• Clinical Ophthalmology Dovepress Dovepress Intravitreal Methotrexate Infusion for Proliferative Vitreoretinopathy Ama Sadaka 1 Robert a Sisk

  year unknowncited by this paper

• Intraocular Methotrexate for the Treatment and Prevention of Proliferative Vitreoretinopathy: A Review

  2022cites this paper